Further Analysis of Sparteine Oxidation in a Japanese Population and Comparison with Data Observed in Different Ethnic Populations

References

• Bertilsson L., Dengler H. J., Eichelbaum M., Schulz H. ‐U. Pharmacogenetic covariation of defective N‐oxidation of sparteine and 4‐hydroxylation of debrisoquine. Europeran Journal of Clinical Pharmocology 1980; 17: 153–155
   PubMed Web of Science ®Google Scholar
• Brosen K. Sparteine oxidation polymorphism in Greenlanders living in Denmark. British Journal of Clinical Pharmacology 1986; 22: 415–419
   PubMed Web of Science ®Google Scholar
• Brosen K., Otton S. V., Gram L. F. Sparteine oxidation polymorphism in Denmark. Acta Pharmacologica et Toxicologica 1985; 57: 357–360
   PubMedGoogle Scholar
• Brosen K., Otton S. V., Gram L. F. Sparteine oxidation polymorphism: a family study. British Journal of Clinical Pharmacology 1986; 21: 661–667
   PubMedGoogle Scholar
• Brosen K., Otton S. V., Gram L. F. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics 1986; 40: 543–549
   PubMed Web of Science ®Google Scholar
• Cooper R. G., Evans D. A. P., Whibley E. J. Polymorphic hydroxylation of perhexiline maleate in man. Journal of Medical Genetics 1984; 21: 27–33
   PubMed Web of Science ®Google Scholar
• Eichelbaum M. Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics 1982; 7: 1–22
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Bertilsson L., Säwe J., Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clinical Pharmacology and Therapeutics 1982; 31: 184–186
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Reetz K. ‐P., Schmidt E. K., Zekorn C. The genetic polymorphism of sparteine metabolism. Xenobiotica 1986; 16: 465–481
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N‐oxidation of sparteine in man: A new pharmacogenitic defect. European Journal of Clinical Pharmacology 1979; 16: 183–187
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Woolhouse M. N. Inter‐ethnic difference in sparteine oxidation among Ghanaians and Germans. European Journal of Clinical Pharmacology 1985; 28: 79–83
   PubMed Web of Science ®Google Scholar
• Evans D. A. P., Harmer D., Downham D. Y., Whibley E. J., Idle J. R., Ritchie J., Smith R. L. The genetic control of spartiene and debrisoquine metabolism in man with new methods of analysing bimodal distribitions. Journal of Medical Genetics 1983; 20: 321–329
   PubMed Web of Science ®Google Scholar
• Evans D. A. P., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics 1980; 17: 102–105
   PubMed Web of Science ®Google Scholar
• Inaba T., Otton S. V., Kalow W. Debrisoquine hydroxylation capacity: Problems of assessment in two populations. Clinical Pharmacology and Therapeutics 1981; 29: 218–223
   PubMedGoogle Scholar
• Inaba T., Vinks A., Otton S. V., Kalow W. Comparative pharmacogenetics of sparteine and debrisoquine. Clinical Pharmacology and Therapeutics 1983; 33: 394–399
   PubMed Web of Science ®Google Scholar
• Ishizaki T., Eichelbaum M., Horai Y., Hashimoto K., Chiba K., Dengler H. J. Evidence for polymorphic oxidation of sparteine in Japanese subjects. British Journal of Clinical Pharmacology 1987; 23: 482–485
   PubMed Web of Science ®Google Scholar
• Jacqz E., Hall S. D., Branch R. A. Genetically determined polymorphisms in drug oxidation. Hepatology 1986; 6: 1020–1032
   PubMed Web of Science ®Google Scholar
• Kalow W. Ethnic differences in drug metabolism. Clinical Pharmacokinetics 1982; 7: 373–400
   PubMed Web of Science ®Google Scholar
• Lennard M. S., Tucker G. T., Silas J. H., Woods H. F. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986; 16: 435–447
   PubMed Web of Science ®Google Scholar
• Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–586
   PubMed Web of Science ®Google Scholar
• Mbanefo C., Bababunmi E. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 1980; 10: 811–818
   PubMed Web of Science ®Google Scholar
• McGourty J. C., Silas J. H., Lennard M. S., Tucker G. T., Woods H. F. Metoprolol metabolism and debrisoquine oxidation polymorphism—population and family studies. British Journal of Clinical Pharmacology 1985; 20: 555–566
   PubMed Web of Science ®Google Scholar
• Mellström B., Bertilsson L., Säwe J., Schulz H. ‐U., Sjöqvist F. E‐ and Z‐10‐hydroxylation of nortripyline: Relationship to polymorphic debrisiquine hydroxylation. Clinical Pharmacology and Therapeutics 1981; 30: 189–193
   PubMed Web of Science ®Google Scholar
• Mellström B., Säwe J., Bertilsson L., Sjöqvist F. Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers. Clinical Pharmacology and Therapeutics 1986; 39: 369–371
   PubMed Web of Science ®Google Scholar
• Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics 1985; 38: 402–408
   PubMed Web of Science ®Google Scholar
• Oates N. S., Shah R. R., Idle J. R., Smith R. L. Genetic polymorphism of phenformine 4‐hydroxylation. Clinical Pharmacology and Therapeutics 1982; 32: 81–89
   PubMed Web of Science ®Google Scholar
• Vinks A., Inaba T., Otton S. V., Kalow W. Sparteine metabolism in Canadian Caucasians. Clinical Pharmacology and Therapeutics 1982; 31: 23–29
   PubMedGoogle Scholar
• Woolhouse N. M., Eichelbaum M., Oates N. S., Idle J. R., Smith R. L. Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clinical Pharmacology and Therapeutics 1985; 37: 512–521
   PubMed Web of Science ®Google Scholar